TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $921,600 | -95.9% | 60,000 | -94.0% | 0.18% | -95.9% |
| Q1 2023 | $22,557,470 | +125.8% | 1,003,000 | +111.2% | 4.43% | +126.2% |
| Q4 2022 | $9,989,250 | -58.0% | 475,000 | -50.8% | 1.96% | -65.8% |
| Q3 2022 | $23,805,000 | +1.2% | 966,108 | -0.5% | 5.73% | +1.6% |
| Q2 2022 | $23,533,000 | -9.6% | 971,233 | -3.8% | 5.64% | -10.3% |
| Q1 2022 | $26,028,000 | +4.8% | 1,010,000 | +26.2% | 6.29% | +14.0% |
| Q4 2021 | $24,832,000 | +63.8% | 800,000 | +28.0% | 5.52% | +56.3% |
| Q3 2021 | $15,156,000 | -4.2% | 625,000 | -42.4% | 3.53% | +6.3% |
| Q2 2021 | $15,820,000 | +6.7% | 1,084,300 | +82.6% | 3.32% | +8.3% |
| Q1 2021 | $14,825,000 | – | 593,712 | – | 3.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |